joining corporate call. start financial XXXX more Thank you, Jennifer summary. then and update financial a good our you for with results We'll us afternoon first a detailed overview appreciate everyone. of an by quarter followed today's We
Cathy Joining me Steve call Mike respective today Whitaker, are on Nadia the of Commercial, Clinical. Regulatory, Melfi, our and and heads Finance, Dac, Jacobsen,
begin receipt we letter. FDA's a package communications. discussions close and post-action in with in we thrombotic the case found in following minutes authority addressed, received cell inaccurate transplant-associated meeting, been dispute Type complete our on a of an them, and other In but we specifically were legal feel or repeated all and we providing the that the view the there briefing number to Yet had addressed own concerns. request When of agency, meeting had New program delayed Drugs. stated FDA that by sponsor with allows TA-TMA. critiques only that the our not stem finally review a we FDA microangiopathy this to our regulatory during new in a their based adequately of A began to minutes also demonstrably higher February, that FDA FDA was we and FDA's official as us. deciding narsoplimab pathway In we Let's final our decision with official meeting division no After response some drafting of MASP-X appeal a an advisers, and resolution division Office had requests.
With established case completing office the specific regulatory the the legal division assistance of and documented out by including believe division, our advisers precedent, lays across not the former our FDA our We components: that request. are all we precedent data, only very and recent regulatory but it strong now draft a FDA directors, and history literature.
the that assessed document input the division strength drafted of and are and strength rapid. this document regulatory is the most legal that our to our of and the of Now, is forward and is on with foregoing design expeditious both proceeding clear. advisers, is the directly we Based path negotiation resolution. have recommendation and our approval. to dispute resolution case position the we on by believe and Dispute our the route We
timing approval respect publishing regulatory process comments regular in prior the is based With Our our submission. required that is request on to existing the of we're advisers and our BLA. to begun have clear data and from incorporating
next the to couple We expect submit within weeks. of
the then is be meeting days the to of according request. are That decision A to held We be within rendered days following of Drugs. XX meeting PDUFA requesting with within a New the should FDA's XX Office meeting. commitments
majority formally & outcome a McNamara, denied sponsor. even the misleading. are Hyman, statistics those the favorable indicate in their that are denied our and & the appeals Burling experience most appeals collective of And at if both statistics of for good advisers public Although, Covington result Phelps
have attempt examples should have especially in in online continue results had medical one requesting recent include pivotal home. who JCO, of in for narsoplimab and and International to the for data Therapy little prior our and Clinical that or the Two transplanters Society with compassionate possible. comprised other to the girls, narsoplimab by fall conferences and and failed group the meantime, to approved Marrow have their the by a Australia, getting the in published been it Transplant flagship TA-TMA one this narsoplimab it, seven-year-old published return provide every and to the been program patients both narsoplimab Cellular of ASTCT of Journal the leading We are Oncology our of Transplantation from our With Held Authored treatment, as two the in the manuscript and of of Research. XXXX. as international defibrotide are had The Lake American premier defibrotide annual JCO journals Center of in children. start joint Italy recently In City, make approved both few confident failed or Blood Tandem days South for able Clinical and the transplanters, one in we submission. other quickly trial the last under was our American year Society and TA-TMA and committed publication were the Tandem Oncology. and a children eculizumab. we believe use We for recovered meetings
narsoplimab the As of in the an understanding award conference, The advancing medical was and crediting and in in keen of president Omeros awareness our part TA-TMA from the field. literature of pharmacists, population which narsoplimab of X,XXX on physicians, though received response the of scientific times Omeros palpable work since the among review of the the than the interest the Tandem the downloaded Society the Transplantation X,XXX aspects TA-TMA, In literature times the raising more for presentation was ASTCT, of than for just and review rigorous website, at groups review narsoplimab than used JCO same March, and from In response weeks natural only the One during European EBMT, received pivotal patient week meeting, patient first pivotal the the times a literature and supportive important definition availability manuscript stringent in had history trial. and more measures, by advocacy the of that in published Conference. patients of underscored who Blood two short our presented. was rate, nurses is narsoplimab newly Marrow or in less for at number a only the TA-TMA XX% were enrolled reported high-risk trial. attendance even
pivotal XX% response refresh a Just in memory, to Omeros your trial that to narsoplimab. found rate
life was saved with report girl old on Another by investigator nine-month EBMT Emory had eculizumab University the case believes narsoplimab. whose was at who a presentation failed a treatment
Omeros of the at physicians, expect effective therapy us we of following approval we and forward community look get All wider availability an searching patients for along to will there. regulatory narsoplimab TA-TMA with that of and caregivers for
III and Enrollment trial Our patients narsoplimab and day. or equal our overall has either least good population that with next patients so target to first half year. baseline made assessing an Phase both continue also proteinuria X ARTEMIS-IGAN approval. IgA the baseline trial data accelerated severe progress. in accelerated than The is support reading is in The of of nephropathy whose to out IgAN more nine-month we program population has on greater proteinuria proteinuria of grams with at X a per gram population can per of is proteinuria regular disease trial or designed day
proving China Our are IgAN also efforts in successful.
application in as and we the enrollment drug remaining to new and investigational and there initiating regulatory soon China look IgAN Our narsoplimab completing possible. for was few forward requirements approved as
background MASP-X ongoing, also has narsoplimab multiple and Collaborative. as Leap Phase to been the drugs evaluated our as is other patients sponsored by COVID-XX show although, in trial in is deprioritized in aHUS for therapy trial. this reported a Narsoplimab X the none hospitalized with Our publicly also trial MASP-X treatment been benefit and of platform reported programs. the date program has relative evaluated to patients therapeutics potential being The I-SPY to trial, relative to have Quantum Healthcare COVID-XX the previously,
we the concurrent in agreement on confirm We We enrollment discussions last with the our narsoplimab with per part that regarding of year, work about can trial Quantum in what the initiated arm, clinical focused are latter stopping in additional Quantum. say treatment can though narsoplimab. limited
much forward. the are Quantum to-date very did data and analysis. go reasons, finalize to that with to would various study report For not collaboratively working We like
include it and complement additional data we the Omeros-Cambridge can, at look Meanwhile, mortality significant in forward for publication the important and cause submitted al. soon COVID and that contributions is A published to Center hyperactivation. the we most as of hyperactivation ability. hyperactivation, COVID-XX fact, that COVID-XX. lectin-pathway to causes and all of sharing As narsoplimab complement infection to the in Research A normalizes by the pathway second function, field's A restoring work trial. now the Frontiers or severe rapidly detailed by the last understanding likely for has complement manuscript, the of of the in Inflammation fighting driven body's delayed morbidity et of secondary is to Complement in provide infection lectin COVID-XX. outcome new continues Ali month in acute SARS-CoV-X mechanism manuscript Immunology that, in demonstrates of been and OCXIR dysfunction pathophysiology
receptive long or world continues COVID also As Biden with around This narsoplimab, or as role and COVID-XX of administration severe advisors, principals discussions COVID-XX groups to resulted from in the lectin potentially, treatment in a pathway PASC. and published, the more increase and the treatment of research specifically, at has interest for is complement more the in acute NIH. demonstrating central prevention of COVID-XX and importance as
and pursue dosing MASP-X good of expected management both MASP-X quarterly to clinic, narsoplimab. Phase even a successfully to range our the us to of our to monthly, long antibody, this in We've is and signal oral made begin summer. advance cycle continues driving of also humans Our on candidate to program as complementary studies, concern, our a once long-acting without toxicology inhibitors, molecule advance for With safety administration nonclinical severe those designed Having lead team small quickly. to we're possible. as advancing OMSXXXX, the a in to trial of progress to MASP-X allows respect planned I second-generation completed With oral acute life soon once for is research COVID-XX. indications OMSXXXX,
now Let's OMIDRIA. to turn
and expenses the OMIDRIA to Surgical Rayner historical with OMIDRIA we royalties last As year-end strategic into a the contract as discontinued on earn call, all of our balance record OMIDRIA asset divestiture well classify revenue the royalty to as The December. as, earnings us Rayner, operations, our required we to reduction completed sheet. discussed, transaction on
Our US royalty of XX%. net sales rate for is OMIDRIA,
revenues the as the in million reclassification as prior zero required the quarter and for expenses, $XX operations our net to quarter. continuing first year loss our of $XX.X revenues Given recorded from and were compared OMIDRIA reported million
$X.XX or Our share or $X.XX per million was last million, share overall loss of $XX first to for the compared year. current quarter in the per $XX.X quarter
a million from change In the expenses cash compared $X.XX noncash last sales $XX.X million decrease for million share, represents million million. reported of $X.X were net over total, Our or an year $XX per year-end in increase approximately, $X.X the and and quarter the investments OMIDRIA sales first our XX% per of This quarter. of XXXX. of to Rayner share. $XX.X the same was $X.XX quarter of first for
at earn of As million. which translates royalties net XX% I sales, $XX.X to mentioned, Rayner we
of As considering in prior we approximately are costs, royalties reduction XX% our receive OMIDRIA and sales. calls, XX% when operating the of net OMIDRIA in profit at we discussed the royalty the when retain operating
operations product to By indications, gone transition we the the with closely minimal Rayner has ensure quarter, disruption with the a very to worked all customers. all of smooth help teams the well. and During transition
OMIDRIA quarter a quarter continue weakest for the to cataract historically for first grow. consequence has and to procedure OMIDRIA as expect and revenues is sales, we been lowest The the typically volume
As support of $XXX.X investments of available we March ongoing XX, operations. XXXX, hand cash to and million had on
As million of XXXX. from a this XX, previously is decrease noted, December $XX
related of quarter, million We royalties be the first $XX.X also which will month. OMIDRIA to collected have receivables, this primarily
earned. forward OMIDRIA of Going XX will within monthly royalties paid days be being
milestone centers years hospital milestone, of Act, if is in of for separate the or the for continuous management pain addition, have the would period eligible used. chambers Omeros introduced renewable outpatient secured well OMIDRIA a a a pays has provide five in and enactment of payment drugs Rayner In as OMIDRIA payment departments receive of which both under One is period $XXX achieved four which surgery in the NOPAIN we been Also, years. like of before million for HOPDs. in not ASCs non-opioid a transaction is OMIDRIA vehicle $XXX commerce, XXXX, the for ASCs, the least agreement, for separate CMS be Currently, or through ambulatory only. separately which terms we as to have $XXX million could sales at million at-the-market
payment expand to more is of for been the patient prevention enactment legislation as enjoys NOPAIN the to NOPAIN bipartisan the agenda XX in this HOPDs support across coalition's Act, and choices member good House of bicameral are and of advance endorsed cosponsors Act and societies part non-opioid the led XX has medical one recently, NOPAIN the and XX sponsors well. organizations Senators nationally voices new of strong and key now Most with it a country. advocacy being has Representatives Representatives. numbering making policy groups would Congress, in Democrat by most and major influential and Efforts summer. separate by legislative caucuses for and than endorsed the the XX the largest legislation recovery The So Coalition the
wrapping up. So
health key programs of scientific passive of the Having portfolio, to industry of the Phase this initiate focused Omeros' After what a and MHRA, in many immuno-oncology summer. antibody clinical source subjects is is MASP-X. on study healthy including and substantial With OMSXXX, addiction. with immunology, our trial PNH, ravulizumab. OMSXXX submitted remain novel Paroxysmal our an move received the the Ib suppression OMIDRIA a the safety CX complement UKs but in MASP-X evaluate or good showed franchise to help believe activator targeting trial is and on have patients which finance already will application to pharmacokinetics pathway authority funding divestiture let's schedule have on from alternative of the in we favorable inhibitor biotech MASP-X our having completed activity, Hemoglobinuria now program, to complement. and the previously pathway and alternative a narsoplimab The advice results discussed premier and Nocturnal our Phase I who high-level a We trial response we unsatisfactory profile.
of there hemolysis. We Phase drug premier data prevent can others or alternative inhibit expect significant advantages effective agents guarantees OMSXXX both be will the expected MASP-X OMSXXX advantages that target While treat extravascular action CX over blood intravascular and our no that to the animal market as will be other well-documented and development market has extravascular we industry to agents been OMSXXX in pathway Two based mechanism leave ability are drugs results, addressing with PNH infection on the safety. inhibitors, and can and expect have on the B blood as make of in or I OMSXXX twice once red the and potential regard the inflammation. PNH. Unlike that reactant And intravascular dosing with shown inhibitors PNH planned the reactants substantially pathway one cell include: to for to that in efficacy. look referred on Those is other to daily can an intact OMSXXX to best other for fluctuate dosed the destruction. Unlike dosing. Unlike leading fighting PNH quarterly to finally, more To dosing is those and meaning precise. are alternative We Factor administration. Three knowledge, response. This over complement forward drugs under challenging acute not adaptive is or phase concentration which MASP-X monthly meaning dosing acute targets once OMSXXX the dosing. twice of those targets be soon. of patients beginning in our immune that interact currently the in systems are phase CX the what of to in weekly
now OMSXXX. to Turning
the phosphodiesterase inhibitor completed program. constraints, the OMSXXX. in development the inhibitors continued successfully study those Phase improve resource exploring we've We Discussions our programs of PDEX models. primate the through program. for of We've for treatment. a treatment in are of dopaminergic not Emory X outcomes XX% of disease. molecule of of Parkinson's PDEX compulsive prioritized with including models Parkinson's of the established relevant also over Parkinson's We're for disorders, broad PDEX that the estate disorders, I but PDEX University, of addiction disease disease. in in inhibitors following funding a modulation of clinical third-party or dyskinesias L-DOPA this prolonged induced use More only In securing lead our our covering we're compounds we've evaluating our Given than improve previously And complement L-DOPA dyskinesias Parkinson's inhibitors shown develop potential regarding motor treatment system. the property of to patients intellectual underway collaboration and previously Parkinson's
Finally, our let's turn to programs. now immuno-oncology
improving of of GPRXXX as the continue therapies. the of one orphan unlocked We means inhibitors we the effectiveness to continue pathway significantly on improve in the including and methods protein-coupled And platform. a XX modulators is G we focus effects adenosine GPCRs cancer receptors to therapies, our to explore that or inhibitors. have tumor receptor of of GPRXXX killing checkpoint current GPCR current
previously response and liquid Mike either detailed Mike? for a explore T receiving may validated advancing which solid and discussion Additionally, cell in results. enforces human the quarter that, therapy a and T technology adoptive property a research or pathway exclusive cell the potency of the cell We I'll that CAR-T intellectual patients has broad and turn Chief our we're for around therapies building to of unexplored improve engineered to this approach and believe cultured mouse systems. top are durability our Jacobsen model approach, financial in T application position We novel we're for Accounting that cells tumor on first call our a aggressive an T Officer through With two continuing the improve our over more technology of to potential therapies. memory platform. phenotypes tumors or novel our to native rates
